ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
Superinvestors holding SPRY, Q2 2026
1 superinvestor reports holding ARS Pharmaceuticals, Inc. on Form 13F, worth $8.01M in total. Weight is ARS Pharmaceuticals, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Third PointDaniel Loeb | 0.2% | 1,000,000 | $8.01M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of SPRY each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2026
1 superinvestor holding at quarter end
- Added
- Third Point (+79.8%)
Q4 2025
1 superinvestor holding at quarter end
- New
- Third Point
Q4 2024
0 superinvestors holding at quarter end
- Sold out
- Duquesne Family Office
Q3 2024
1 superinvestor holding at quarter end